Skip to main content
Erschienen in: Neurological Sciences 1/2014

01.05.2014 | FICEF SYMPOSIUM - Headache in the front line: from pharmacist to general practitioner

Symptomatic treatment of migraine: from scientific evidence to patient management

verfasst von: Gian Camillo Manzoni, P. Torelli

Erschienen in: Neurological Sciences | Sonderheft 1/2014

Einloggen, um Zugang zu erhalten

Abstract

All migraine patients need symptomatic treatment to stop individual attacks or, at least, significantly relieve pain. When attacks are very frequent (more than 3 days of headache per month on average), they will also need preventive treatment. The first physician the patient must address to for preventive treatment is the general practitioner (GP). If the medication prescribed by the GP is not effective or there is overuse of symptomatic drugs, the patient will have to be referred to a neurologist or a headache clinic. The drugs to be used as symptomatic treatment are triptans and non-steroidal anti-inflammatory drugs. Combination therapy with antiemetics is also important. While specialists will base their therapeutic decisions on guidelines in the literature and on their personal experience, GPs do not yet have any easy-to-use tools to support them. To fill this gap, an algorithm is proposed here that can be easily used by GPs to make decisions during their patients’ migraine attacks.
Literatur
1.
Zurück zum Zitat Lipton RB, Stewart WF, Simon D (1998) Medical consultation for migraine: results from the American Migraine Study. Headache 38:87–96PubMedCrossRef Lipton RB, Stewart WF, Simon D (1998) Medical consultation for migraine: results from the American Migraine Study. Headache 38:87–96PubMedCrossRef
2.
Zurück zum Zitat Seng EK, Holroyd KA (2013) Optimal use of acute headache medication: a qualitative examination of behaviors and barriers to their performance. Headache 53:1438–1450PubMed Seng EK, Holroyd KA (2013) Optimal use of acute headache medication: a qualitative examination of behaviors and barriers to their performance. Headache 53:1438–1450PubMed
3.
Zurück zum Zitat Torelli P, Manzoni GC (2012) A redefinition of primary headache: chronic migraine. Neurol Sci 33:S17–S20PubMedCrossRef Torelli P, Manzoni GC (2012) A redefinition of primary headache: chronic migraine. Neurol Sci 33:S17–S20PubMedCrossRef
4.
Zurück zum Zitat Manzoni GC, Grisendi I, Torelli P (2011) ICHD-3: what changes do we need regarding migraine? Curr Pain Headache Rep 15:170–176PubMedCrossRef Manzoni GC, Grisendi I, Torelli P (2011) ICHD-3: what changes do we need regarding migraine? Curr Pain Headache Rep 15:170–176PubMedCrossRef
5.
Zurück zum Zitat Antonaci F, Valade D, Lanteri-Minet M, Láinez JM, Jensen R, Steiner TJ (2008) European Headache Federation and Lifting The Burden: the global campaign to reduce the burden of headache worldwide. Proposals for the organisation of headache services in Europe. Intern Emerg Med 3:S25–S28PubMedCrossRef Antonaci F, Valade D, Lanteri-Minet M, Láinez JM, Jensen R, Steiner TJ (2008) European Headache Federation and Lifting The Burden: the global campaign to reduce the burden of headache worldwide. Proposals for the organisation of headache services in Europe. Intern Emerg Med 3:S25–S28PubMedCrossRef
6.
Zurück zum Zitat Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS (2009) EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol 16:968–981PubMedCrossRef Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A, Sandor PS (2009) EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur J Neurol 16:968–981PubMedCrossRef
7.
Zurück zum Zitat Agenzia Nazionale per i Servizi Sanitari Regionali (Age.na.s) (2011) Cefalea nell’adulto: Linee guida nazionali di riferimento per la prevenzione e la terapia Agenzia Nazionale per i Servizi Sanitari Regionali (Age.na.s) (2011) Cefalea nell’adulto: Linee guida nazionali di riferimento per la prevenzione e la terapia
8.
Zurück zum Zitat Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E (2012) Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78:1337–1345PubMedCentralPubMedCrossRef Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E (2012) Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78:1337–1345PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Abrignani G, Ferrante T, Castellini P, Lambru G, Beghi E, Manzoni GC, Torelli P (2012) Description and validation of an Italian ICHD-II based questionnaire for use in epidemiological research. Headache 52:1262–1282PubMedCrossRef Abrignani G, Ferrante T, Castellini P, Lambru G, Beghi E, Manzoni GC, Torelli P (2012) Description and validation of an Italian ICHD-II based questionnaire for use in epidemiological research. Headache 52:1262–1282PubMedCrossRef
10.
Zurück zum Zitat Greppi E, Sicuteri F (1964) L’emicrania. Motivi di fisiopatogenesi e di terapia. Relazione al 65°Congresso della Società Italiana di Medicina Interna Greppi E, Sicuteri F (1964) L’emicrania. Motivi di fisiopatogenesi e di terapia. Relazione al 65°Congresso della Società Italiana di Medicina Interna
11.
Zurück zum Zitat Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT (2010) A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med 56:1–6PubMedCrossRef Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendron RT (2010) A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med 56:1–6PubMedCrossRef
Metadaten
Titel
Symptomatic treatment of migraine: from scientific evidence to patient management
verfasst von
Gian Camillo Manzoni
P. Torelli
Publikationsdatum
01.05.2014
Verlag
Springer Milan
Erschienen in
Neurological Sciences / Ausgabe Sonderheft 1/2014
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-014-1734-4

Weitere Artikel der Sonderheft 1/2014

Neurological Sciences 1/2014 Zur Ausgabe

SESSION IV UNCONVENTIONAL TREATMENTS

Herbal therapy in migraine

SYMPOSIUM Botulinum toxin in clinical practice

The setting of a botulinum toxin treatment service

SESSION I HEADACHE AT WORK AND AT SCHOOL

Headache in school age

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.